clinical trial · NCT05082584
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
Anemia of Chronic Kidney DiseaseVadadustat
brief summary
This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of chronic kidney disease (CKD) naive to erythropoiesis-stimulating agent (ESA) treatment.
started
Jan 1, 2025
primary completion
Jul 1, 2026
completion
Oct 1, 2026
last updated
Oct 1, 2025
official title
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol